Agenus Inc.
Anti-CTLA-4 antibodies and methods of use thereof

Last updated:

Abstract:

The instant disclosure provides antibodies that specifically bind to human CTLA-4 and antagonize CTLA-4 function. Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.

Status:
Grant
Type:

Utility

Filling date:

24 Apr 2020

Issue date:

8 Mar 2022